This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
Vivian Xie
18 Aug 2022

Breaking the ground for WuXi STA’s new pharmaceutical facility in Delaware

WuXi AppTec subsidiary and leading CRDMO, WuXi STA, has broken the ground at the site for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware.  

WuXi STA, a subsidiary of WuXi AppTec based in Shanghai, China, have broken the ground for their latest 190-acre pharmaceutical manufacturing campus in Middletown Delaware. The project was announced in June 2021 and promises WuXi STA’s second facility in the United States to offer expanded capacity and greater flexibility for their customers.

The new, state-of-the-art facility will offer approximately 500 full-time jobs by 2026, and provide a site for formulation development, clinical and commercial drug product manufacturing services in addition to packaging, labelling and storage and distribution for clinical trial and commercial drug materials and products. With 12 sites across the United States, Europe, and Asia, WuXi STA hopes to continue offering their services across the globe. 

WuXi STA specializes in pharmaceutical development and manufacturing capabilities, offering solutions for integrated chemical, manufacturing, and controls as a premier CRDMO. Parent company WuXi AppTec operates with a global portfolio of research and development and manufacturing services for the pharmaceutical and healthcare industries to advance discoveries and manufacturing, delivering essential therapies to patients.  

Delaware Governor John Carney commented: “The biopharmaceutical industry is part of Delaware’s DNA… Over the next 5 years, WuXi STA plans to build a state-of-the-art pharmaceutical manufacturing campus in one of Delaware’s fastest-growing communities, bringing with it good jobs and economic growth.” 

Minzhang Chen, co-CEO of WuXi AppTec and CEO of WuXi STA, added: “I would like to thank our federal, state, and local partners in Delaware for their continued support in the establishment of this site… WuXi STA continues to increase our capabilities and capacities to better serve our customers through a more robust and reliable supply chain. With our integrated contract research, development, and manufacturing organization platform and proven quality system, we look forward to working with our customers to swiftly deliver their innovative therapies to market in order to save lives and improve healthcare for patients.  

Source: WuXi STA (stapharma.com) 

Related News